Chargement en cours...
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy. First‐ and second‐generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the...
Enregistré dans:
| Publié dans: | Oncologist |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AlphaMed Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156184/ https://ncbi.nlm.nih.gov/pubmed/29650685 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0582 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|